Sydney, Australia - Novotech, the leading Asia Pacific centred biotech CRO conducted a survey of global biotech professionals, in partnership with Citeline, on their current and future clinical pipeline prospects, the main challenges of clinical trials, and perspective shifts regarding study locations.
A key finding from the report is that cost is the number one concern for 32% of respondents, followed by patient recruitment at 29%.
The report shares insights into the trends and pain points in biotech clinical trials, as companies seek to secure funding for continued and future development.
Key areas covered include:
- Modalities: current pipeline vs. future investment
- Top clinical trial operational challenges
- The role of APAC: China and Australia offer key advantages
- Clinical trial and CRO strategy success factors
The report also covers trends and industry professionals’ perceptions across therapeutic areas.
For example according to the report: “When asked about the most promising therapy type for future investment and development, CGTs took the top spot (26%), followed by mRNA (22%) and antibody therapeutics (19%).”
Novotech offers biotechs a unique and unparalleled suite of early to late-phase CRO services across the US and Europe, with a focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.
Novotech has been benchmarked as a top 10 CRO among the world’s leading CROs, is the recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award and the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed 45 Leading Site Partnership agreements over the last 3 years.
Media contact
Toyna Chin
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase.
With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations.
Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies.
Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results
For more information or to speak to an expert team member visit www.Novotech-CRO.com